BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development - HT9425-23-S-SOC1

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9425-23-S-SOC1-0003

NAICS

-

Classification Code

AN12

Additional Details
Set Aside

NONE

Place of Performance

-

SourceSAM
Documents5
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a Broad Agency Announcement (BAA) titled "Extramural Biomedical and Human Performance Research and Development" (HT9425-23-S-SOC1). This BAA seeks to solicit innovative extramural research and development ideas that advance biomedical and human performance knowledge, leveraging the authority provided by United States Code, Title 10, Section 4001. The announcement is issued in accordance with the Competition in Contracting Act of 1984 and relevant Federal Acquisition Regulations, specifically FAR 6.102(d)(2) and 35.016. The primary purpose of this BAA is to fund basic and applied research projects that support scientific study and experimentation, with the goal of advancing the state-of-the-art or increasing understanding in biomedical and human performance domains. Importantly, the focus is on generating new knowledge and insights rather than developing specific systems or hardware solutions. The intended outcomes are to benefit both military and civilian medical practice, contributing to broader scientific and clinical advancements. The scope of the BAA encompasses a wide range of research areas relevant to the United States Special Operations Command (USSOCOM), as detailed in the BAA and its associated documents. The announcement outlines research areas of interest, evaluation and selection criteria, and provides comprehensive instructions for pre-proposal and full proposal submissions, as well as general administrative guidance. Key requirements for participation include the mandatory submission of a pre-proposal through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org/. Pre-proposals may be submitted at any time during the BAA’s five-year open period, which runs from August 1, 2023, through July 31, 2028. Following review, selected offerors will be invited to submit a full proposal or application via Grants.gov. Only invited full proposals will be considered, and these must be submitted through the Grants.gov portal (http://www.grants.gov/). The BAA, including revised research areas of interest and the General Submission Instructions, is available for download on Grants.gov by searching for opportunity number HT9425-23-S-SOC1. There are no set-aside requirements associated with this opportunity, making it open to all eligible entities. The procurement is classified under Product Service Code AN12, which pertains to research and development in the biomedical field. The contracting entity for this opportunity is the Defense Health Agency, a federal office within the Department of Defense. The primary point of contact for inquiries is the eBRAP Help Desk, which can be reached via email at [email protected] or by phone at 301-682-5507. This BAA represents a significant opportunity for organizations engaged in biomedical and human performance research to contribute to advancements that will inform and enhance both military and civilian healthcare. Contractors considering this opportunity should ensure their research aligns with the stated objectives and submission requirements, and are encouraged to review all associated documents available on Grants.gov for detailed guidance. For further information and to access the full announcement, interested parties should visit the official SAM.gov listing at: https://sam.gov/opp/dad75d85b3294322ad0a70bcfb5ebd7e/view.